What is FAP Kdpharma Group
Par un écrivain mystérieux
Description
Familial Adenomatous Polyposis (FAP) is a hereditary condition that results in the early development of polyps and colorectal cancer that could starts at the early age of 12 years old. FAP is considered as an orphan disease, with a prevalence of 0,6/1,0 out of 10.000. Caused by germline mutations in the APC gene it is characterized by the development of hundreds to thousands of polyps and carriers of the APC gene mutation, if not treated appropriately, will develop colorectal cancer. Unfortunately at the moment there is no safe treatment available.
Familial Adenomatous Polyposis Drugs in Development by Stages
Leader in Pharmaceutical Omega 3 Manufacturing
KD Pharma Group & SLA Pharma Initiate Clinical Trial For COVID-19
Pharmaceutical Products and CDMO services- KD Pharma Group
Leader in Pharmaceutical Omega 3 Manufacturing
Promising fish oil-based coronavirus treatment heads to clinical
SLA Pharma
KD Pharma Group - capiton
Daniele Polettini on LinkedIn: KD Pharma CDMO Division
Complementation Dependent Enzyme Prodrug Therapy Enables Targeted
Leader in Pharmaceutical Omega 3 Manufacturing
Daniele Polettini on LinkedIn: KD Pharma CDMO Division
KD Pharma Group
Justin Slagel on LinkedIn: BIO-Europe Spring 2023
KD Pharma Group
depuis
par adulte (le prix varie selon la taille du groupe)
